NanoViricides, Inc.: A First-In-Class, Broad-Spectrum Antivi

Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum

Related Keywords

United States , India , Japan , Japanese , American , Sulfated Proteoglycans , Theracour Pharma Inc , European Medicines Agency , Drug Administration , Committee For Medicinal Products Human , Securities Exchange , Virus Killing Technology Platform , Exchange Commission , Nanoviricides Inc , Novel Host Mimetic , Virus Killing Technology , Mimetic Technology To Solve , Greatest Pain , Antiviral Medicines , Broad Antiviral Spectrum , Phasei Human Clinical Trials , Executive Chairman , Karveer Meditech , Human Immunodeficiency Virus , Hepatitisb Virus , Hepatitisc Virus , Herpes Simplex Virus , Varicella Zoster Virus , Asian Bird Flu Virus , Japanese Encephalitis , West Nile Virus , Theracour Pharma , Securities Act , Securities Exchange Act , United States Securities , Good Manufacturing , Medicinal Products , Human Use , Relations Contact , Ihr Portfolio ,